On January 19, 2021, Theratechnologies Inc. (TSX:TH; NASDAQ:THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced the closing of a bought deal public offering (the “Offering”), pursuant to which Theratechnologies issued 16,727,900 units (the “Units”) at a price of US$2.75 per Unit (equivalent to approximately C$3.51 per Unit) (the “Offering Price”) for aggregate gross proceeds of US$46,001,725 (equivalent to approximately C$58,714,929), including the full exercise of the over-allotment option to purchase an additional 2,181,900 Units at the Offering Price.
Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company (each whole warrant, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of US$3.18 (equivalent to approximately C$4.06) at any time until January 19, 2024.
The Offering was led by Mackie Research Capital Corporation as the lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and National Bank Financial Inc.
Miller Thomson advised the syndicate of underwriters with a team comprised of Geoff Clarke, Jonathan Tong, Brandon Meyer, Syed Rizvi and Erin Elias (Capital Markets & Securities); Karen Durell (Intellectual Property); and Manjit Singh (Tax).
